Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras
AuthorsEscribà, Josep M
Romero, Alberto de Dios
Viñas, Pedro Albajar
Palma, Pedro Pablo
Lima, M Angeles
AffiliationMédécins Sans Frontières, Barcelona, Spain; Central Reference Laboratory for Chagas Disease and Leishmaniasis; National Chagas Disease Prevention and Control Program, Secretariat of Health, Tegucigalpa, Honduras; Laboratório de Doenças Parasitarias - Medicina Tropical, Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro, RJ, Brasil
MetadataShow full item record
AbstractBetween 1999-2002, Médécins Sans Frontières-Spain implemented a project seeking to determine the efficacy and safety of benznidazole in the treatment of recent chronic Chagas disease in a cohort of seropositive children in the Yoro Department, Honduras. A total of 24,471 children were screened for Trypanosoma cruzi IgG antibodies through conventional enzyme-linked immunosorbent assays (ELISA) on filter paper. Recombinant ELISA (0.93% seroprevalence) showed 256 initially reactive cases, including 232 confirmed positive cases. Of these, 231 individuals were treated with benznidazole (7.5 mg/kg/day) for 60 days and were followed with a strict weekly medical control and follow-up protocol. At the end of the project, 229 patients were examined by the Honduras Secretariat of Health for post-treatment serological assessments; 88.2% seroconverted after 18 months and 93.9% seroconverted after three years. No differences were found in the seroconversion rates according to age or sex. Most of the side effects of the treatment were minor. These results support the argument that in areas where T. cruzi I is predominant and in areas affected by T. cruzi II, when vector transmission has been interrupted, Chagas disease diagnosis and treatment are feasible, necessary and ethically indisputable.
- Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.
- Authors: Yun O, Lima MA, Ellman T, Chambi W, Castillo S, Flevaud L, Roddy P, Parreño F, Albajar Viñas P, Palma PP
- Issue date: 2009 Jul 7
- Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.
- Authors: de Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, Almeida IC, de Andrade SS, de Andrade JG, Martelli CM
- Issue date: 1996 Nov 23
- High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala.
- Authors: Brum-Soares L, Cubides JC, Burgos I, Monroy C, Castillo L, González S, Viñas PA, Urrutia PP
- Issue date: 2016 Nov-Dec
- Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
- Authors: Sguassero Y, Cuesta CB, Roberts KN, Hicks E, Comandé D, Ciapponi A, Sosa-Estani S
- Issue date: 2015
- Benznidazole treatment in chronic children infected with Trypanosoma cruzi: serological and molecular follow-up of patients and identification of Discrete Typing Units.
- Authors: Rumi MM, Pérez Brandán C, Gil JF, D'Amato AM, Ragone PG, Lauthier JJ, Tomasini N, Cimino RO, Orellana V, Lacunza CD, Nasser JR, Basombrío MA, Diosque P
- Issue date: 2013 Oct